Certara (NASDAQ:CERT) Sets New 52-Week Low – Should You Sell?

Certara, Inc. (NASDAQ:CERT) reached a new 52-week low during trading on Thursday . The stock traded as low as $5.20 and last traded at $5.2150, with a volume of 498620 shares traded. The stock had previously closed at $5.43.

Wall Street Analyst Weigh In

Several research firms have recently commented on CERT. Wall Street Zen downgraded Certara from a “buy” rating to a “hold” rating in a research note on Sunday, February 15th. Barclays reaffirmed an “equal weight” rating and issued a $8.00 price objective on shares of Certara in a research note on Friday, March 6th. Craig Hallum downgraded Certara from a “buy” rating to a “hold” rating and set a $10.00 price objective on the stock. in a research note on Friday, February 27th. KeyCorp decreased their price objective on Certara from $13.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, January 8th. Finally, Leerink Partners reaffirmed an “outperform” rating and issued a $10.00 price objective on shares of Certara in a research note on Thursday, February 26th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Certara currently has an average rating of “Hold” and a consensus price target of $11.10.

Certara Stock Down 2.3%

The firm has a market capitalization of $844.24 million, a P/E ratio of -529.50 and a beta of 1.62. The company has a 50 day simple moving average of $6.68 and a two-hundred day simple moving average of $8.97. The company has a current ratio of 2.05, a quick ratio of 2.05 and a debt-to-equity ratio of 0.27.

Certara (NASDAQ:CERT) last released its quarterly earnings results on Thursday, February 26th. The company reported $0.09 earnings per share for the quarter, missing the consensus estimate of $0.11 by ($0.02). The firm had revenue of $103.65 million for the quarter, compared to analysts’ expectations of $103.23 million. Certara had a negative net margin of 0.38% and a positive return on equity of 4.20%. The business’s quarterly revenue was up 3.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.15 EPS. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. On average, equities analysts predict that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Hedge Funds Weigh In On Certara

Institutional investors have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. grew its holdings in Certara by 2,733.3% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,975 shares of the company’s stock valued at $26,000 after buying an additional 2,870 shares in the last quarter. First Horizon Corp purchased a new position in Certara during the 3rd quarter valued at approximately $30,000. Versant Capital Management Inc grew its holdings in Certara by 66.7% during the 3rd quarter. Versant Capital Management Inc now owns 2,881 shares of the company’s stock valued at $35,000 after buying an additional 1,153 shares in the last quarter. Osaic Holdings Inc. grew its holdings in Certara by 50.7% during the 2nd quarter. Osaic Holdings Inc. now owns 3,491 shares of the company’s stock valued at $41,000 after buying an additional 1,175 shares in the last quarter. Finally, Global Retirement Partners LLC grew its holdings in Certara by 45.0% during the 3rd quarter. Global Retirement Partners LLC now owns 5,636 shares of the company’s stock valued at $69,000 after buying an additional 1,749 shares in the last quarter. Hedge funds and other institutional investors own 73.96% of the company’s stock.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.